Ocular surface damage

Ocular surface damage is not a molecule, receptor, or canonical therapeutic target. Instead, it describes the injury or pathological changes affecting the outermost layers of the eye—primarily the cornea and conjunctiva—which can result from various ocular surface diseases such as dry eye syndrome, blepharitis, neurotrophic keratitis, and others[1][3][7]. This damage may manifest as pain, redness, poor vision, and in severe cases can lead to permanent corneal or conjunctival injury[7]. The underlying causes are diverse and include tear film instability/deficiency (as in dry eye), inflammation, infection, trauma, autoimmune conditions affecting tear production/glands (e.g., Sjögren’s syndrome), eyelid disorders like blepharitis or meibomian gland dysfunction[2][5]. Treatments focus on addressing these underlying causes rather than targeting "ocular surface damage" itself with drugs aimed at specific molecules/receptors. Therefore "ocular surface damage" is best understood as an outcome of disease processes rather than a discrete druggable biological entity. > “Ocular surface disease indicates damage to the surface layers of the eye... Damage to the epithelium can cause pain...and ultimately can lead to permanent corneal or conjunctival injury. Treatment depends on the underlying cause...”[7] > “Dry eyes may occur if you don't produce enough tears or if you produce poor-quality tears. This tear instability leads to inflammation and **damage of the eye's surface**.”[9]

Other names

Ocular surface diseaseOSDDry eye (in some contexts)Keratoconjunctivitis sicca (in some contexts)